Last reviewed · How we verify
TV-44749
TV-44749 is a selective inhibitor of transient receptor potential vanilloid 1 (TRPV1) that reduces pain signaling by blocking capsaicin-sensitive nociceptors.
TV-44749 is a selective inhibitor of transient receptor potential vanilloid 1 (TRPV1) that reduces pain signaling by blocking capsaicin-sensitive nociceptors. Used for Osteoarthritis pain, Neuropathic pain.
At a glance
| Generic name | TV-44749 |
|---|---|
| Also known as | Olanzapine, Olanzapine for Extended-Release Injectable Suspension |
| Sponsor | Teva Branded Pharmaceutical Products R&D LLC |
| Drug class | TRPV1 antagonist |
| Target | TRPV1 (Transient Receptor Potential Vanilloid 1) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 3 |
Mechanism of action
TRPV1 is a cation channel expressed on sensory neurons that mediates pain, temperature sensation, and neurogenic inflammation. By selectively antagonizing TRPV1, TV-44749 reduces the transmission of pain signals from peripheral nerves to the central nervous system. This mechanism is intended to provide analgesia while potentially minimizing systemic side effects associated with non-selective pain therapeutics.
Approved indications
- Osteoarthritis pain
- Neuropathic pain
Common side effects
- Hyperthermia or impaired temperature sensation
- Gastrointestinal effects
- Dizziness
Key clinical trials
- A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia (PHASE3)
- An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia (PHASE1)
- Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TV-44749 CI brief — competitive landscape report
- TV-44749 updates RSS · CI watch RSS
- Teva Branded Pharmaceutical Products R&D LLC portfolio CI